triazoles has been researched along with oxidopamine in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.00) | 18.7374 |
| 1990's | 5 (20.00) | 18.2507 |
| 2000's | 10 (40.00) | 29.6817 |
| 2010's | 8 (32.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hamilton, TC; Longman, SD | 1 |
| di Chiara, G; Morelli, M; Pinna, A; Wardas, J | 1 |
| Fenu, S; Morelli, M; Ongini, E; Pinna, A | 1 |
| Cristalli, G; Morelli, M; Pinna, A; Wardas, J | 1 |
| Fenu, S; Morelli, M | 1 |
| Bloch, B; Fourreau, L; Fredholm, BB; Gonon, F; Le Moine, C; Svenningsson, P | 1 |
| Fenu, S; Morelli, M; Pinna, A | 1 |
| Morelli, M; Pinna, A | 1 |
| Corsi, C; Gianfriddo, M; Melani, A; Morelli, M; Pedata, F; Pinna, A | 1 |
| Carta, AR; Morelli, M; Pinna, A; Tronci, E | 1 |
| Bastia, E; Chen, JF; Fredduzzi, S; Moratalla, R; Ongini, E; Schwarzschild, MA; Yu, L | 1 |
| Chang, H; Conlon, PR; Engber, TM; Haque, S; Kiesman, WF; Kumaravel, G; Petter, RC; Sha, L; Wang, J; Whalley, ET; Yao, G | 1 |
| Dexter, DT; Dhankot, A; Gillies, GE; McArthur, S; Murray, HE | 1 |
| Jenner, P; Ramsay Croft, N; Rose, S | 1 |
| Asai, M; Matsuya, T; Miyoshi, S; Mizoguchi, H; Murakami, Y; Nagai, T; Nishimura, S; Noda, A; Sato, K; Takuma, K; Yamada, K | 1 |
| Borsini, F; Carminati, P; Frau, L; Morelli, M; Schintu, N; Simola, N; Tronci, E | 1 |
| Cristalli, G; Morelli, M; Pinna, A; Pontis, S; Schintu, N; Simola, N; Tronci, E; Volpini, R | 1 |
| Dziubina, A; Gołembiowska, K | 1 |
| Bhattacharjee, AK; Chen, X; Jacobson, KA; Jacobson, O; Kiesewetter, DO; Lang, L; Ma, Y; Niu, G; Shinkre, B; Trenkle, WC | 1 |
| Amalric, M; Blobaum, AL; Bode, J; Bridges, TM; Bubser, M; Conn, PJ; Daniels, JS; Dickerson, JW; Engers, DW; Hopkins, CR; Italiano, K; Jadhav, S; Jones, CK; Lindsley, CW; Morrison, RD; Niswender, CM; Thompson, AD; Turle-Lorenzo, N | 1 |
| Downey, P; Michel, A; Nicolas, JM; Scheller, D | 1 |
| Borsini, F; Caprioli, A; Di Serio, S; Lombardo, K; Minetti, P; Pace, S; Riccioni, T; Stasi, MA; Vertechy, M | 1 |
| A Figge, D; Standaert, DG | 1 |
| Agostinho, P; Andrade, GM; Canas, PM; Carmo, M; Cunha, RA; Duarte, FV; Fernandes, FD; Gonçalves, FQ; Oses, JP; Palmeira, CM; Tomé, AR | 1 |
| Contu, L; Costa, G; Morelli, M; Pinna, A; Serra, M | 1 |
25 other study(ies) available for triazoles and oxidopamine
| Article | Year |
|---|---|
A comparison of the cardiovascular and sedative actions of the alpha-adrenoceptor agonists, FLA-136 and clonidine, in the rat.
Topics: Adrenergic alpha-Agonists; Animals; Blood Pressure; Clonidine; Drug Interactions; Heart Rate; Hemodynamics; Hydroxydopamines; Hypnotics and Sedatives; Injections, Intraventricular; Male; Methohexital; Naloxone; Oxidopamine; Rats; Rats, Inbred Strains; Triazoles; Yohimbine | 1982 |
Blockade of A2a adenosine receptors positively modulates turning behaviour and c-Fos expression induced by D1 agonists in dopamine-denervated rats.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Denervation; Male; Motor Activity; Nerve Tissue Proteins; Oxidopamine; Proto-Oncogene Proteins c-fos; Purinergic P1 Receptor Antagonists; Pyrimidines; Quinazolines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Rotation; Triazoles; Xanthines | 1996 |
Adenosine A2A receptor antagonism potentiates L-DOPA-induced turning behaviour and c-fos expression in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Behavior, Animal; Brain Diseases; Dopamine Agonists; Drug Synergism; Gene Expression; Genes, fos; Levodopa; Male; Oxidopamine; Proto-Oncogene Proteins c-fos; Purinergic P1 Receptor Antagonists; Pyrimidines; Quinpirole; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptors, Dopamine D2; Substantia Nigra; Triazoles | 1997 |
Adenosine A2A receptor agonists increase Fos-like immunoreactivity in mesolimbic areas.
Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Animals; Dopamine Agonists; Immunohistochemistry; Limbic System; Male; Oxidopamine; Phenethylamines; Proto-Oncogene Proteins c-fos; Purinergic Antagonists; Purinergic P1 Receptor Agonists; Pyrimidines; Quinpirole; Rats; Rats, Sprague-Dawley; Triazoles | 1997 |
Motor stimulant effects of caffeine in 6-hydroxydopamine-lesioned rats are dependent on previous stimulation of dopamine receptors: a different role of D1 and D2 receptors.
Topics: Animals; Apomorphine; Caffeine; Central Nervous System Stimulants; Dopamine Agonists; Male; Motor Activity; Oxidopamine; Purinergic P1 Receptor Antagonists; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D1; Receptors, Dopamine D2; Rotation; Stimulation, Chemical; Triazoles; Xanthines | 1998 |
Opposite tonic modulation of dopamine and adenosine on c-fos gene expression in striatopallidal neurons.
Topics: Adenosine; Animals; Antiparkinson Agents; Corpus Striatum; Dopamine; Dopamine Agonists; Drug Design; Gene Expression Regulation; Genes, fos; Globus Pallidus; In Situ Hybridization; Male; Models, Neurological; Nerve Tissue Proteins; Neurons; Oxidopamine; Proto-Oncogene Proteins c-fos; Purinergic P1 Receptor Antagonists; Pyrimidines; Quinolines; Rats; Rats, Wistar; Receptor, Adenosine A2A; Receptors, Dopamine D2; RNA, Messenger; Triazoles; Tyrosine 3-Monooxygenase | 1999 |
Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats.
Topics: Animals; Dopamine Agents; Drug Tolerance; Levodopa; Male; Motor Activity; Neuroprotective Agents; Oxidopamine; Purinergic P1 Receptor Antagonists; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Stereotyped Behavior; Sympathectomy, Chemical; Triazoles | 2001 |
Interaction between dopamine and adenosine A2A receptors as a basis for the treatment of Parkinson's disease.
Topics: Animals; Antiparkinson Agents; Denervation; Dopamine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Drug Tolerance; Levodopa; Male; Motor Activity; Neostriatum; Neural Pathways; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Purinergic P1 Receptor Antagonists; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptors, Purinergic P1; Substantia Nigra; Sympatholytics; Triazoles | 2001 |
Adenosine A2A receptor antagonism increases striatal glutamate outflow in dopamine-denervated rats.
Topics: Animals; Corpus Striatum; Denervation; Dopamine; Glutamic Acid; Male; Microdialysis; Oxidopamine; Purinergic P1 Receptor Antagonists; Pyrimidines; Rats; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Receptors, Purinergic P1; Time Factors; Triazoles | 2003 |
Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats.
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Basal Ganglia; Behavior, Animal; Denervation; Disease Models, Animal; Dopamine; Dose-Response Relationship, Drug; Gene Expression; Glutamate Decarboxylase; Isoenzymes; Levodopa; Motor Activity; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Pyrimidines; Rats; Receptor, Adenosine A2A; Receptors, Dopamine; RNA, Messenger; Time; Triazoles | 2003 |
Adenosine A2A receptors in neuroadaptation to repeated dopaminergic stimulation: implications for the treatment of dyskinesias in Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Amphetamine; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Tolerance; Dyskinesia, Drug-Induced; Humans; Levodopa; Mice; Mice, Knockout; Neurons; Neuroprotective Agents; Oxidopamine; Parkinsonian Disorders; Purines; Pyrimidines; Receptor, Adenosine A2A; Synapses; Triazoles | 2003 |
Synthesis of alkyne derivatives of a novel triazolopyrazine as A(2A) adenosine receptor antagonists.
Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Alkynes; Animals; Catalepsy; Cerebral Cortex; Disease Models, Animal; Mice; Oxidopamine; Parkinson Disease; Pyrazines; Rats; Structure-Activity Relationship; Triazoles | 2005 |
Striatal susceptibility to a dopaminergic neurotoxin is independent of sex hormone effects on cell survival and DAT expression but is exacerbated by central aromatase inhibition.
Topics: Anastrozole; Animals; Aromatase; Aromatase Inhibitors; Cell Survival; Corpus Striatum; Dopamine; Dopamine Plasma Membrane Transport Proteins; Drug Resistance; Estrogens; Female; Male; Nerve Degeneration; Neural Pathways; Neuronal Plasticity; Neurotoxins; Nitriles; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Sprague-Dawley; Sex Characteristics; Substantia Nigra; Triazoles | 2007 |
The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats.
Topics: Adenine; Adenosine; Adenosine A2 Receptor Antagonists; Animals; Brain; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Drug Synergism; Exploratory Behavior; Levodopa; Male; Movement; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptor, Adenosine A2A; Sympatholytics; Triazoles | 2007 |
Synergistic effects of adenosine A2A antagonist and L-DOPA on rotational behaviors in 6-hydroxydopamine-induced hemi-Parkinsonian mouse model.
Topics: Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Disease Models, Animal; Drug Synergism; Levodopa; Male; Mice; Mice, Inbred ICR; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Pyrimidines; Receptor, Adenosine A2A; Rotation; Triazoles | 2007 |
Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Adrenergic Agents; Animals; Antiparkinson Agents; Behavior, Animal; Corpus Striatum; Dynorphins; Enkephalins; Glutamate Decarboxylase; Isoenzymes; Levodopa; Male; Oxidopamine; Parkinson Disease, Secondary; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tacrine; Tremor; Triazoles | 2007 |
A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Adenine; Animals; Antiparkinson Agents; Autoradiography; Behavior, Animal; Brain Chemistry; CD11b Antigen; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Early Growth Response Protein 1; Gene Expression Regulation; Jaw; Levodopa; Male; Mice; Mice, Inbred C57BL; Motor Activity; Movement; Nerve Degeneration; Nerve Tissue Proteins; Neuroprotective Agents; Oxidopamine; Parkinson Disease; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; RNA, Messenger; Rotarod Performance Test; Time Factors; Triazoles; Vibrissae | 2010 |
Effect of adenosine A(2A) receptor antagonists and L-DOPA on hydroxyl radical, glutamate and dopamine in the striatum of 6-OHDA-treated rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Benserazide; Caffeine; Dopamine; Glutamic Acid; Hydroxyl Radical; Levodopa; Male; Microdialysis; Neostriatum; Oxidopamine; Parkinsonian Disorders; Rats; Rats, Wistar; Receptor, Adenosine A2A; Triazines; Triazoles | 2012 |
Striatal adenosine A(2A) receptor-mediated positron emission tomographic imaging in 6-hydroxydopamine-lesioned rats using [(18)F]-MRS5425.
Topics: Animals; Autoradiography; Biological Transport; Injections; Male; Neostriatum; Oxidopamine; Positron-Emission Tomography; Pyrazoles; Pyrimidines; Quinpirole; Raclopride; Radiochemistry; Rats; Receptor, Adenosine A2A; Triazoles | 2011 |
The metabotropic glutamate receptor 4-positive allosteric modulator VU0364770 produces efficacy alone and in combination with L-DOPA or an adenosine 2A antagonist in preclinical rodent models of Parkinson's disease.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adenosine A2 Receptor Antagonists; Animals; Brain; Calcium Signaling; Catalepsy; Corpus Striatum; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; G Protein-Coupled Inwardly-Rectifying Potassium Channels; Glutamic Acid; Haloperidol; HEK293 Cells; Humans; Levodopa; Male; Monoamine Oxidase; Motor Neuron Disease; Oxidopamine; Parkinson Disease; Picolinic Acids; Protein Binding; Psychomotor Performance; Pyrimidines; Rats; Rats, Sprague-Dawley; Rats, Wistar; Reaction Time; Receptors, G-Protein-Coupled; Receptors, Metabotropic Glutamate; Substantia Nigra; Thallium; Transfection; Triazoles; Tyrosine 3-Monooxygenase | 2012 |
Unprecedented therapeutic potential with a combination of A2A/NR2B receptor antagonists as observed in the 6-OHDA lesioned rat model of Parkinson's disease.
Topics: Adenosine A2 Receptor Antagonists; Analysis of Variance; Animals; Benzothiazoles; Drug Therapy, Combination; Levodopa; Mass Spectrometry; Motor Activity; Oxidopamine; Parkinson Disease, Secondary; Piperidines; Purines; Pyrimidines; Rats; Receptors, N-Methyl-D-Aspartate; Triazoles | 2014 |
Animal models of Parkinson׳s disease: Effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535).
Topics: Adenine; Adenosine A2 Receptor Antagonists; Administration, Oral; Animals; Antiparkinson Agents; Basal Ganglia; Binding, Competitive; Catalepsy; Cyclic AMP; Disease Models, Animal; Dose-Response Relationship, Drug; Haloperidol; HEK293 Cells; Humans; Injections, Intraperitoneal; Ligands; Male; Mice; Motor Activity; Oxidopamine; Parkinsonian Disorders; Protein Binding; Rats, Sprague-Dawley; Receptor, Adenosine A2A; Transfection; Triazoles | 2015 |
Dysregulation of BET proteins in levodopa-induced dyskinesia.
Topics: Animals; Antiparkinson Agents; Azepines; Chromatin Immunoprecipitation; Corpus Striatum; Disease Models, Animal; Dyskinesia, Drug-Induced; Levodopa; Male; Oxidopamine; Parkinsonian Disorders; Protein Domains; Proteins; Rats, Sprague-Dawley; Real-Time Polymerase Chain Reaction; RNA, Messenger; Transcription, Genetic; Triazoles | 2017 |
Enhanced ATP release and CD73-mediated adenosine formation sustain adenosine A
Topics: 5'-Nucleotidase; Adenosine; Adenosine A2 Receptor Antagonists; Adenosine Diphosphate; Adenosine Triphosphate; Animals; Cell Line, Tumor; Humans; Male; Oxidopamine; Parkinsonian Disorders; Pyrimidines; Rats, Wistar; Receptor, Adenosine A2A; Triazoles | 2019 |
Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT
Topics: Adenosine A2 Receptor Antagonists; Animals; Antiparkinson Agents; Calcium-Binding Proteins; Caudate Nucleus; Dyskinesia, Drug-Induced; Glial Fibrillary Acidic Protein; Interleukin-10; Interleukin-1beta; Levodopa; Microfilament Proteins; Neuroinflammatory Diseases; Oxidopamine; Parkinsonian Disorders; Pars Compacta; Piperazines; Putamen; Pyrimidines; Rats; Receptor, Serotonin, 5-HT1A; Receptor, Serotonin, 5-HT1B; Serotonin 5-HT1 Receptor Agonists; Triazoles; Tumor Necrosis Factor-alpha | 2021 |